Compass Pathways price target lowered to $7 by BTIG on drug concerns

BTIG lowered its price target on Compass Pathways (CMPS) to $7.00 from $12.00, while maintaining a Buy rating, due to concerns over its COMP360 drug development. The firm views COMP360 as "mediocre" relative to other pipeline options, despite acknowledging impressive consistency between Phase 2b and Phase 3 results in treatment-resistant depression. BTIG anticipates COMP360's market will primarily be limited to patients who have already tried ketamine, and highlighted emerging competition from potentially equally effective, easier-to-use drugs with lighter or no psychedelic effects, which could constrain CMPS's long-term market share.

Analysis

BTIG has materially revised its outlook on Compass Pathways, lowering its price target by 41.7% to $7.00 from $12.00 while paradoxically maintaining a Buy rating. The downgrade stems from concerns that the company's lead drug, COMP360, is a "mediocre drug" in a competitive landscape that includes both psychedelic and non-psychedelic alternatives. While the firm notes the impressive consistency between Phase 2b and Phase 3 trial data—highlighting a MADRS reduction of approximately 4 units—this result is viewed as positioning the drug's efficacy as merely equivalent to existing treatments like SPRAVATO. Consequently, BTIG anticipates COMP360's addressable market will be confined to treatment-resistant depression patients who have already tried ketamine, limiting its near-term commercial scope. Compounding this concern is the emergence of compelling data from private competitors like Gilgamesh, whose drugs may offer similar efficacy with more favorable administration profiles (lighter or no psychedelic effects), posing a significant long-term threat to COMP360's market share.

Key Decisions for Investors

• Investors should view the maintained 'Buy' rating with caution, as the sharp price target cut to $7.00 reflects significant concerns about COMP360's commercial viability and competitive positioning.
• Factor in the specific market limitation cited, as COMP360's expected positioning for post-ketamine patients suggests a niche market rather than a first-line blockbuster, which should temper revenue forecasts.
• Closely monitor the competitive landscape, particularly clinical data from firms like Gilgamesh, as the development of easier-to-use treatments represents a primary long-term risk to CMPS's value proposition.